A global study co-led by the Chinese University of Hong Kong has demonstrated that the targeted therapy lorlatinib can prevent disease progression in over half of advanced lung cancer patients for at least seven years. This significant advancement suggests the potential to manage advanced lung cancer as a chronic illness, similar to conditions like diabetes. The research involved 296 patients across multiple regions, comparing lorlatinib against crizotinib, with the former showing a 55% progression-free survival rate at seven years versus 3% for the control. AI
RANK_REASON The cluster reports on findings from a clinical trial published in a study, which is a research milestone. [lever_c_demoted from research: ic=1 ai=0.1]
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
